CVKD NASDAQ
Cadrenal Therapeutics, Inc. Common Stock
1W: -16.1%
1M: -27.5%
3M: -71.3%
YTD: -86.8%
1Y: -93.1%
3Y: -90.4%
$0.94
-0.03 (-3.07%)
Weekly Expected Move ±13.1%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-01-25
Earliest Filing
2025-12-11
Latest Filing
partner: 5
target: 2
investor: 1
Counterparties (Filed by CVKD)
8 relationshipsCompanies named in CVKD's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Veralox Therapeutics Inc. | — | target | Seller of assets including intellectual property and compounds related to VLX-1005 | 2025-12-11 | View |
| Old Dominion University | — | partner | Licensor of patent rights related to 12-LOX inhibitors | 2025-12-11 | View |
| Eastern Virginia Medical School | ELOG | partner | Original Licensor of patent rights, succeeded by Old Dominion University | 2025-12-11 | View |
| eXIthera Pharmaceuticals, Inc. | — | target | Seller of assets including intellectual property and exclusive license rights for compounds Frunexian and EP-7327 | 2025-09-15 | View |
| Sichuan Haisco Pharmaceutical Co., Ltd. | — | partner | Counterparty to the exclusive license agreement for development and commercialization of Frunexian in China | 2025-09-15 | View |
| Abbott Global Enterprises Limited | — | partner | Collaboration Agreement for Phase 3 study on tecarfarin in LVAD patients | 2025-03-04 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for the Company's At the Market Offering Agreement | 2024-03-12 | View |
| HESP LLC | — | investor | Received unregistered shares of common stock | 2023-01-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-29 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-08-31 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-17 | Officer/Director Change; Exhibits | View | |
| 2026-07-10 | Officer/Director Change; Exhibits | View | |
| 2026-07-01 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-06-29 | Officer/Director Change; Exhibits | View | |
| 2026-06-18 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-03 | Officer/Director Change; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-30 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-01 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-03-31 | Earnings Release; Exhibits | View | |
| 2026-03-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-02-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-16 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-12-11 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2025-12-01 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR